XML 80 R47.htm IDEA: XBRL DOCUMENT v3.25.0.1
Revenue Recognition (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2014
Disaggregation of Revenue [Line Items]        
Total net revenue $ 358,711 $ 310,463 $ 331,339  
Milestone fees paid 220,000 220,000    
U.S.        
Disaggregation of Revenue [Line Items]        
Milestone fees paid $ 120,000 $ 120,000    
Net Product Sales | Geographic Concentration Risk | U.S.        
Disaggregation of Revenue [Line Items]        
Concentration Risk, Percentage 83.00% 91.00%    
Net Product Sales | Geographic Concentration Risk | Rest of the world        
Disaggregation of Revenue [Line Items]        
Concentration Risk, Percentage 17.00% 9.00%    
Royalty revenue        
Disaggregation of Revenue [Line Items]        
Total net revenue $ 241,733 $ 238,846 311,645  
GIAPREZA        
Disaggregation of Revenue [Line Items]        
Total net revenue 55,037 41,294 14,214  
XERAVA        
Disaggregation of Revenue [Line Items]        
Total net revenue 21,385 17,320 5,480  
XACDURO        
Disaggregation of Revenue [Line Items]        
Total net revenue 21,070 2,003 0  
GSK        
Disaggregation of Revenue [Line Items]        
Total net revenue $ 241,733 $ 238,846 $ 311,645  
GSK | Long-Acting Beta2 Agonist (LABA) Collaboration        
Disaggregation of Revenue [Line Items]        
Milestone fees paid       $ 220,000
Percentage of economic interest in any future payments made under the agreements 15.00%      
GSK | RELVAR/BREO | Long-Acting Beta2 Agonist (LABA) Collaboration        
Disaggregation of Revenue [Line Items]        
Royalty rate for first level of annual global net sales (as a percent) 15.00%      
Annual global sales level used to determine royalty rate $ 3,000,000      
Royalty rate for sales above first level of annual global net sales (as a percent) 5.00%      
GSK | ANORO | Long-Acting Beta2 Agonist (LABA) Collaboration | Minimum        
Disaggregation of Revenue [Line Items]        
Royalty rate for combination products (as a percent) 6.50%      
GSK | ANORO | Long-Acting Beta2 Agonist (LABA) Collaboration | Maximum        
Disaggregation of Revenue [Line Items]        
Royalty rate for combination products (as a percent) 10.00%      
GSK | TRELEGY | Long-Acting Beta2 Agonist (LABA) Collaboration | Minimum        
Disaggregation of Revenue [Line Items]        
Royalty rate for combination products (as a percent) 6.50%      
GSK | TRELEGY | Long-Acting Beta2 Agonist (LABA) Collaboration | Maximum        
Disaggregation of Revenue [Line Items]        
Royalty rate for combination products (as a percent) 10.00%      
La Jolla [Member] | Net Product Sales | Geographic Concentration Risk | U.S.        
Disaggregation of Revenue [Line Items]        
Concentration Risk, Percentage     96.00%  
La Jolla [Member] | Net Product Sales | Geographic Concentration Risk | Rest of the world        
Disaggregation of Revenue [Line Items]        
Concentration Risk, Percentage     4.00%